Positive news from the laboratory was the wind beneath the wings of Novo Nordisk (NVO 2.96%) stock on Thursday. The Denmark-based pharmaceutical company, famed for its Ozempic and Wegovy drugs, saw its share price improve by nearly 3% on the day after it reported the results of a late-stage clinical trial. That rise easily bettered the 0.4% gain of the S&P 500 index.Amycretin is advancingThat news concerned amycretin, an investigational weight-loss drug that would represent a step up from the highly popular ...